We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Illumina, Inc.

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Additionally, Illumina — alongside the rest of the biotech industry — is facing uncertainty amidst looming cuts to research funding and grants, primarily from the National Institutes of Health ...

Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

China’s Ministry of Commerce said it would ban Illumina, a San Diego company, from importing its gene-mapping products in China. Illumina is the world’s leading producer of gene-sequencing ...

Barclays views Illumina’s (ILMN) guidance last night as largely as expected. The bulls are going to defend the stock on China being de-risked, but Barclays still see risk with National ...

But for biotech firm Illumina, a leading maker of gene-sequencing equipment, it has been a barrage of bad news. The company was already grappling with fierce competition and slowing growth ...

Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.